News - Oncology

Filter

Current filters:

Oncology

Popular Filters

60 to 84 of 1474 results

UK NICE backs Janssen’s Velcade for multiple myeloma

UK NICE backs Janssen’s Velcade for multiple myeloma

21-03-2014

In new draft guidance published today, UK drugs watchdog the National Institute for Health and Care Excellence…

JanssenJohnson & JohnsonNorthern EuropeOncologyPharmaceuticalPricingRegulationUKVelcade

Report: Action must be taken to improve treatments for bladder cancer

Report: Action must be taken to improve treatments for bladder cancer

20-03-2014

There is an urgent need for new drugs for bladder cancer, according to a new paper published in European…

OncologyPharmaceuticalResearchUK

GlaxoSmithKline’s MAGE-A3 fails in Ph III NSCLC trial

GlaxoSmithKline’s MAGE-A3 fails in Ph III NSCLC trial

20-03-2014

There was another setback for UK pharma giant GlaxoSmithKline with its MAGE-A3 antigen specific cancer…

AgenusGlaxoSmithKlineMAGE-A3OncologyPharmaceuticalResearch

Latest Australian PBS Listings include medicines for children

Latest Australian PBS Listings include medicines for children

19-03-2014

Ten new medicines to treat a range of illnesses from rare forms of cancer to skin conditions will be…

Anti-Arthritics/RheumaticsAsia-PacificAustraliaDermatologicalsDiabetesGastro-intestinalsHealthcareOncologyPharmaceuticalPricing

Executive Q&A: ADC Therapeutics’ chief executive Michael Forer

Executive Q&A: ADC Therapeutics’ chief executive Michael Forer

19-03-2014

In an interview with The Pharma Letter, CEO Michael Forer discusses ADC Therapeutics' developing pipeline…

ADC TherapeuticsBiotechnologyInterviewsNorthern EuropeOncology

Added benefit for non-pre-treated Yervoy patients in advanced melanoma not proven, says IQWiG

Added benefit for non-pre-treated Yervoy patients in advanced melanoma not proven, says IQWiG

19-03-2014

The German Institute for Quality and Efficiency in Health Care (IQWiG) has re-assessed the added benefit…

Bristol-Myers SquibbGermanyNorthern EuropeOncologyPharmaceuticalPricingRegulationYervoy

Astellas and Medivation file sNDA for new Xtandi indication

Astellas and Medivation file sNDA for new Xtandi indication

18-03-2014

Japanese drug major Astellas Pharma and US partner Medivation have filed a supplemental New Drug Application…

Astellas PharmaMedivationNorth AmericaOncologyPharmaceuticalRegulationUSAXtandi

Asia-Pacific NSCLC market to reach $2.9 billion by 2019

Asia-Pacific NSCLC market to reach $2.9 billion by 2019

18-03-2014

The non-small cell lung cancer (NSCLC) therapeutics market value in the Asia-Pacific (APAC) region -…

Asia-PacificAustraliaChinaIndiaJapanMarkets & MarketingOncologyPharmaceutical

Additional indication in Japan for Kyowa Hakko’s Poteligeo

Additional indication in Japan for Kyowa Hakko’s Poteligeo

18-03-2014

Japanese drugmaker Kyowa Hakko Kirin has received approval for additional indication for relapsed or…

Kyowa Hakko KirinOncologyPharmaceuticalPoteligeoRegulation

Medimmune announces research deals with University of Cambridge and University of Texas

Medimmune announces research deals with University of Cambridge and University of Texas

18-03-2014

USA-based MedImmune, the global biologics research and development arm of Anglo-Swedish drug major AstraZeneca,…

MedImmuneOncologyPharmaceuticalResearchUKUSA

Five Prime rockets on immuno-oncology deal with Bristol-Myers Squibb

Five Prime rockets on immuno-oncology deal with Bristol-Myers Squibb

17-03-2014

Shares of Five Prime Therapeutics leapt 15% to $21.48 in early trading, after the company said it has…

Bristol-Myers SquibbFive Prime TherapeuticsLicensingMergers & AcquisitionsOncologyPharmaceutical

Pharma Summit: Merck’s European president Bruno Strigini highlights importance of innovation

Pharma Summit: Merck’s European president Bruno Strigini highlights importance of innovation

17-03-2014

The president of pharma giant Merck & Co’s (NYSE: MRK) operations in Europe and Canada Bruno Strigini…

Anti-viralsCanadaDiabetesEuropeInterviewsMerck & CoMK-3475OncologyPharmaceuticalRegulationUKVaccines

NICE draft guidance recommends Boehringer Ingelheim’s Giotrif

NICE draft guidance recommends Boehringer Ingelheim’s Giotrif

17-03-2014

UK drugs watchdog the National Institute for Health and care Excellence (NICE) this morning issued new…

Boehringer IngelheimGiotrifNorthern EuropeOncologyPharmaceuticalPricingRegulationUK

Retrospective analysis shows tumor shrinkage with Amgen's talimogene laherparepvec

Retrospective analysis shows tumor shrinkage with Amgen's talimogene laherparepvec

16-03-2014

Leading independent biotech firm Amgen says that findings from a pre-specified retrospective analysis…

AmgenBiotechnologyOncologyResearchtalimogene laherparepvec

AnaptysBio and Tesaro team up in $340 million oncology deal

14-03-2014

Therapeutic antibody discoverer AnaptysBio announced a strategic immuno-oncology collaboration with fellow…

AnaptysBioBiotechnologyImmunologicalsLicensingOncologyTesaro

ArQule’s tivantinib in HCC not affected by MetMab’s fall, say analysts

ArQule’s tivantinib in HCC not affected by MetMab’s fall, say analysts

14-03-2014

Swiss drug major Roche’s (ROG: SIX) recent decision to stop the Phase III METLung trial, which tested…

ArQuleOncologyPharmaceuticalResearchtivantinib

NICE says better information needed on Celgene’s MM drug

NICE says better information needed on Celgene’s MM drug

14-03-2014

The UK drugs watchdog, the National Institute for Health and care Excellence (NICE) says that, based…

BiotechnologyCelgeneNorthern EuropeOncologyPricingRegulationRevlimidUK

UK cancer drug companies combine expertise in merger

UK cancer drug companies combine expertise in merger

13-03-2014

UK oncology company Incanthera says it has acquired Onco-NX, the University of Salford drug discovery…

IncantheraMergers & AcquisitionsOnco-NXOncologyPharmaceutical

OXiGENE leaps on increased survival results for Zybrestat

OXiGENE leaps on increased survival results for Zybrestat

12-03-2014

Shares of US biotech firm OXiGENE rocketed 88.8% to $4.59 after the company announced positive results…

BiotechnologyOncologyOXiGENEResearchZybrestat

Geron nosedives on FDA clinical hold for blood disorders drug imetelstat

Geron nosedives on FDA clinical hold for blood disorders drug imetelstat

12-03-2014

USA-based Geron Corp saw its shares plunge 59% to $1.79 when the company revealed that it had received…

BiotechnologyGeron CorpimetelstatNorth AmericaOncologyRegulationResearchUSA

Nexavar disappoints in Ph III liver cancer study

Nexavar disappoints in Ph III liver cancer study

11-03-2014

German pharma major Bayer and Onyx Pharmaceuticals, now a subsidiary of US biotech firm Amgen say that…

AmgenBayerNexavarOncologyOnyx PharmaceuticalsPharmaceuticalResearch

Idelalisib may represent promising treatment for stubborn blood cancers

11-03-2014

A pill that suppresses a key regulator of cancer growth may provide hope to relapsed leukemia and lymphoma…

BiotechnologyGilead SciencesHematologyidelalisibOncologyResearch

Ph III study for Jakavi meets endpoint in patients with polycythemia vera

Ph III study for Jakavi meets endpoint in patients with polycythemia vera

07-03-2014

Swiss pharma major Novartis today announced positive results from a pivotal Phase III trial of Jakavi…

IncyteJakaviNovartisOncologyPharmaceuticalRare diseasesRegulationResearch

AstraZeneca to establish cancer research program with Korea’s HIDI

AstraZeneca to establish cancer research program with Korea’s HIDI

07-03-2014

Anglo-Swedish pharma major AstraZeneca has signed a memorandum of understanding (MoU) with the South…

Asia-PacificAstraZenecaOncologyPharmaceuticalResearch

60 to 84 of 1474 results

Company Spotlight

Fibrotech

Fibrotech

Back to top